Connectus Wealth LLC sells 5,528 shares of Johnson & Johnson (NYSE: JNJ)


Connectus Wealth LLC reduced its stake in Johnson & Johnson (NYSE:JNJGet a rating) by 11.7% during the 1st quarter, according to the company in its last filing with the SEC. The fund held 41,824 shares of the company after selling 5,528 shares during the period. Connectus Wealth LLC’s holdings in Johnson & Johnson were worth $7,171,000 when it last filed with the SEC.

Several other hedge funds and other institutional investors have also recently changed their holdings in the company. Family CFO Inc acquired a new stake in shares of Johnson & Johnson during the 4th quarter at a value of $26,000. Steward Financial Group LLC acquired a new position in Johnson & Johnson during Q4 worth approximately $34,000. Professional Financial Advisors LLC increased its stake in Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company worth $37,000 after purchasing 68 additional shares during the period. Joseph P. Lucia & Associates LLC acquired a new position in Johnson & Johnson during Q1 worth approximately $38,000. Finally, Advocacy Wealth Management Services LLC increased its stake in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company worth $41,000 after purchasing an additional 67 shares during the period. Institutional investors hold 68.78% of the company’s shares.

Analyst upgrades and downgrades

A number of research analysts have recently published reports on the company. Raymond James raised his price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a Wednesday, April 20 research note. UBS Group reduced its price target on Johnson & Johnson from $185.00 to $180.00 in a Thursday, July 21 report. Wells Fargo & Company raised its price target on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a Wednesday, July 13 report. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 report. Finally, Morgan Stanley raised its price target on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a Friday, July 8 research note. Four investment analysts gave the stock a hold rating, five gave the company a buy rating and one gave the company a high buy rating. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Insider buying and selling

In related news, EVP Kathryn E. Wengel sold 40,000 Johnson & Johnson shares in a trade dated Friday, June 10. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the SEC, available at this link. In a similar vein, Executive Vice President Kathryn E. Wengel sold 40,000 Johnson & Johnson shares in a trade dated Friday, June 10. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the SEC, available at this link. Also, CAD Robert J. Decker sold 8,462 Johnson & Johnson shares in a trade dated Thursday, May 26. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. Disclosure of this sale can be found here. 0.35% of the shares are currently held by insiders.

Johnson & Johnson trades down 1.1%

Shares of JNJ Stock opened at $165.30 on Friday. The company has a debt ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. The stock’s 50-day simple moving average is $174.47 and its two-hundred-day simple moving average is $174.68. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a market capitalization of $434.60 billion, a PE ratio of 24.06, a growth price-earnings ratio of 3.24 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet a rating) last released its quarterly earnings data on Tuesday, July 19. The company reported earnings per share of $2.59 for the quarter, beating analyst consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company posted revenue of $24.02 billion in the quarter, versus $23.85 billion expected by analysts. In the same quarter last year, the company achieved EPS of $2.48. The company’s quarterly revenue increased 3.0% year over year. Research analysts predict that Johnson & Johnson will post earnings per share of 10.05 for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Investors of record on Tuesday, August 23 will receive a dividend of $1.13. The ex-date of this dividend is Monday, August 22. This represents an annualized dividend of $4.52 and a dividend yield of 2.73%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Johnson & Johnson profile

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Read more

Want to see what other hedge funds hold JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJGet a rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Comments are closed.